Rajeshwar P. Mookerjee1, Marco Pavesi2, Karen Louise Thomsen1, Gautam Mehta1, Jane Macnaughtan1, Flemming Bendtsen3, Minneke Coenraad4, Jan Sperl5, Pere Gines6,7,8,9, Richard Moreau10,11,12,13, Vicente Arroyo2, Rajiv Jalan1,*, для исследовательской группы CANONIC консорциума EASL-CLIF
1 Liver Failure Group, UCL Institute for Liver and Digestive Health, UCL Medical School, Royal Free Hospital, London, United Kingdom; 2 European Foundation for the Study of Chronic Liver Failure (EF-CLIF) and EASL-CLIF Consortium; 3 Department of Gastroenterology, Hvidovre Hospital, University of Copenhagen, Copenhagen, Denmark; 4 Department of Gastroenterology-Hepatology, Leiden University Medical Center, Leiden, The Netherlands; 5 Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; 6 Liver Unit, Hospital Clinic de Barcelona, University de Barcelona, Barcelona, Spain; 7 University of Barcelona, Barcelona, Spain; 8 Institut d’Investigacions Biomediques August Pi I Sunyer (IDIBAPS), Barcelona, Spain; 9 Centro d’Investigacion Biomedica en Red Enfermedades Hepaticas y Digestivas (CIBEReHD), Barcelona, Spain; 10 Inserm, U1149, Centre de Recherche sur l’Inflammation (CRI), Clichy and Paris, France; 11 UMRS1149, Universite Paris Diderot-Paris 7, Paris, France; 12 Departement Hospitalo-Universitaire (DHU) UNITY, Service d’Hepatologie, Hopital Beaujon, Assistance Publique-Hopitaux de Paris, Clichy, France; 13 Laboratoire d’Excellence Inflamex, PRES Sorbonne Paris Cite, Paris, France
◊ Приглашенный редактор: Didier Samuel.
17.06.16